| 摘要 |
<p num="1"><br/><br/><br/>The present invention is directed to compounds of formula (I), or a <br/>pharmaceutically acceptable salt, prodrug, salt of a prodrug, or combination <br/>thereof, wherein Y is selected from the group consisting of-CRxRy-, -C(O)-, -O-<br/>, -N(H)-, -N(alkyl)- and -S-; wherein each of Rx and Ry is independently <br/>selected from the group consisting of hydrogen. alkyl, hydroxyalkyl, and <br/>haloalkyl; or Rx and Ry together with the carbon to which they are attached <br/>form a monocyclic cycloalkyl or heterocycle ring, Ar1 is selected from the <br/>group consisting of phenyl and a monocyclic, five or six- membered heteroaryl, <br/>Ar3 is phenyl or monocyclic heteroaryl, wherein Ar3 is substituted with 1, 2, <br/>3 or 4 substituents Ar2 is a group of formula (a), (b), (c), (d), or (e); <br/>wherein R is hydrogen, cycloalkyj, alkyl or haloalkyl, Z1, Z2, Z3 and Z4 are <br/>C(R101), or one or two of Z1, Z2, Z3 and Z4 is N and the others are C(R101); <br/>Z5, Z6 and Z7 are C(102). or one or two of Z5, Z6 and Z7 are N, and the others <br/>are C(R102), Z is selected from the group consisting of -OR5, -alkylenyl-OR5, -<br/>N(R6)(R7) and -alkylenyI-N(R6)(R7), which inhibit acetyl-CoA carboxylase (ACC) <br/>and are useful for the prevention or treatment of metabolic syndrome, type II <br/>diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.<br/>
|
